![Feature image](https://www.fatetherapeutics.com/wp-content/uploads/2017/06/Bob-Valamehr-1.jpg)
Dr. Valamehr presented Fate Therapeutics’ proprietary iPSC platform, which is designed for the consistent and scalable generation of iPSCs for off-the-shelf therapeutic use. He also reviewed Fate’s proprietary technology for the highly efficient differentiation of genetically-engineered iPSCs into cells of the hematopoietic lineage, including Natural Killer (NK) and T cell-based immunotherapy product candidates.